


PHARMACEUTICAL 2018

AKORN INC Rank 63 of 349







RealRate

PHARMACEUTICAL 2018

AKORN INC Rank 63 of 349

The relative strengths and weaknesses of AKORN INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AKORN INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 264% points. The greatest weakness of AKORN INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 103% points.

The company's Economic Capital Ratio, given in the ranking table, is 56%, being 333% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	730,151
Cost of Goods Sold	407,898
Intangible Assets	854,794
Liabilities, Current	171,089
Liabilities, Non-Current	907,177
Other Assets	11,148
Other Compr. Net Income	7,999
Other Expenses	124,783
Other Liabilities	0
Other Net Income	-36,326
Property and Equipment	313,418
Research and Development	80,502
Revenues	841,045
Selling, General and Administrative Expense	216,086

Output Variable	Value in 1000 USD
Assets	1,909,511
Liabilities	1,078,266
Expenses	829,269
Stockholders Equity	831,245
Net Income	-24,550
Comprehensive Net Income	-20,550
Economic Capital Ratio	56%

